17:33 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Sarcoma; pancreatic cancer In vitro and mouse studies identified an amiloride-based PLAU inhibitor that could help treat metastatic fibrosarcoma and pancreatic cancers. Chemical synthesis and in vitro testing of amiloride analogs in enzyme activity...
08:00 , Nov 12, 2015 |  BC Innovations  |  Product R&D

Probodies, anticancer

Lauren Martz, Senior Writer  How successful checkpoint inhibitors and chimeric antigen receptor (CAR) T cells will be at revolutionizing oncology hangs largely on whether it will be possible to curb their on-target but off-tissue toxicities....
07:00 , Jul 14, 2014 |  BC Week In Review  |  Company News

Wilex, RedHill deal

Wilex granted RedHill exclusive rights to develop and commercialize Mesupron outside of Taiwan and China, including Hong Kong and Macau. Wilex will receive $1 million up front and is eligible for tiered royalties from the...
07:00 , May 12, 2014 |  BC Week In Review  |  Clinical News

A6: Phase II started

Angstrom began an open-label, U.S. Phase II trial to evaluate subcutaneous A6 twice daily in 28-day cycles for 6 cycles in about 20 patients. Angstrom Pharmaceuticals Inc. , San Diego, Calif.   Product: A6  ...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Company News

Link Health, Wilex deal

Wilex granted Link Health exclusive rights to develop and commercialize Mesupron in Taiwan and China, including Hong Kong and Macau, for all cancer indications. Wilex is eligible for an upfront payment and milestones totaling more...
08:00 , Feb 3, 2014 |  BC Week In Review  |  Company News

Wilex cancer news

Wilex will reduce headcount by 41 (80%) to 10 at its headquarters in Munich. The company said it would discontinue clinical development "stepwise" but declined to provide details on specific early stage programs. Wilex will...
07:00 , Mar 11, 2013 |  BioCentury  |  Regulation

Dissecting Kadcyla

Two and a half years after FDA refused to file Genentech Inc. 's BLA for accelerated approval of Kadcyla ado-trastuzumab emtansine in metastatic breast cancer, the agency has granted full approval - and outlined its...
08:00 , Nov 15, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Bicyclic peptides conjugated to an albumin-binding peptide to extend serum half-life A study in mice suggests conjugating bicyclic peptides to an albumin-binding peptide could increase...
07:00 , Oct 22, 2012 |  BC Week In Review  |  Clinical News

Girentuximab: Phase III data

Wilex said an independent DMC has recommended terminating the double-blind, international Phase III ARISER trial in 864 clear cell RCC patients after IV Rencarex missed the trial's primary endpoint of improving median DFS vs. placebo....
00:45 , Oct 17, 2012 |  BC Extra  |  Top Story

Wilex plummets on Rencarex miss

Wilex AG (Xetra:WL6) fell EUR 2.40 (62%) to EUR 1.50 on Tuesday after Rencarex girentuximab missed the primary endpoint of improving median disease-free survival (DFS) vs. placebo in the Phase III ARISER trial to treat...